搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Yahoo Finance
5 小时
ASH 2024: AstraZeneca set to take a BiTE out of follicular lymphoma market
At the 2024 annual meeting of the American Society of Hematology (ASH), held on 7 December in San Diego, California, ...
FiercePharma
1 天
ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia
Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
ENDPOINTS NEWS
16 小时
AstraZeneca reveals first clinical data for bispecific T cell engager ...
AstraZeneca is getting ready to step on the gas in the world of bispecific T cell engagers. The company presented some of its ...
FiercePharma
4 天
AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited-stage small cell ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
4 天
FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
FierceBiotech
3 天
AstraZeneca, Daiichi share data behind Dato-DXd do-over amid 2nd bid for lung cancer approval
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
腾讯网
3 天
40年来重大突破!阿斯利康重磅免疫疗法再获FDA批准
▎药明康德内容团队编辑阿斯利康(AstraZeneca)今日宣布其重磅PD-L1抑制剂Imfinzi(durvalumab)已获得美国FDA的批准,用于治疗接受铂类同步放化疗(cCRT)后病情未进展的局限期小细胞肺癌(LS-SCLC)成人患者。小细胞 ...
7 小时
Priority FDA review given to AstraZeneca’s Imfinzi sBLA for MIBC
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...
8 小时
AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation
"The breakthrough therapy designation granted by the FDA underscores the significant unmet need for new treatments for patients with previously treated EGFR-mutated non-small cell lung cancer who have ...
6 小时
AstraZeneca, Daiichi Sankyo announce BTD for datopotamab deruxtecan
Datopotamab deruxtecan has been granted Breakthrough Therapy Designation, or BTD, in the U.S. for the treatment of adult patients with locally ...
Daily
3 天
AstraZeneca Imfinzi gets USFDA nod for limited-stage small cell lung cancer
AstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small ...
4 天
FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer
Imfinzi (durvalumab) for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈